The Swiss diabetes hardware company Ypsomed is selling off its insulin pen needle and blood sugar monitoring operations, as it turns its attention toward its drug autoinjectors and digital insulin ...
Auto-injector specialist Ypsomed is hopping on the U.S. manufacturing bandwagon, investing 200 million Swiss francs ($248 million) to build a plant in Holly Springs, North Carolina. It will be the ...
Sept 20 (Reuters) - Swiss medical technology company Ypsomed YPSN.S announced on Wednesday a long-term supply deal with Novo Nordisk NOVOb.CO for autoinjectors, the latest sign of how the Danish ...
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...
Lannett has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin ...
Novo Nordisk has spent the last two years scrambling to keep up with skyrocketing demand for its blockbuster GLP-1 drugs, the obesity-focused Wegovy and Type 2 diabetes med Ozempic, forcing it to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results